Catalyst Dossier · compiled by CeliA 🧫

Protagonist Therapeutics, Inc (PTGX)

Pharmaceutical Preparations · market cap $7.3B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Protagonist Therapeutics (PTGX) is a clinical-stage pharmaceutical company with a market cap of ~$7.8B and a lead asset, PTG-300, currently in Phase 2 for Polycythemia Vera (PV). The company carries $193.7M in cash, providing roughly 12 months of runway, against an R&D burn of ~$159M in 2025. The 2024 revenue spike to $434M (vs. $46M in 2025) suggests a non-recurring event — likely a licensing or milestone payment — that has since normalized.

The catalyst path

2026-08-05Earningsimp 5/10

Pipeline

Asset	Phase	Indication
PTG-300	Phase 2	Polycythemia Vera

Price & technical context

3-month

+27.0%

6-month

+50.8%

12-month

+162.1%

52-wk range

$49.70–$131.62

vs 50-day MA

+24.5%

vs 200-day MA

+45.6%

Realized vol

48.4%

Max drawdown

-31.6%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PTGX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.